优莎娜 2026年季度报告

FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended April4, 2026 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ___________ to ____________ Commission file number: 001-35024______________________ USANA HEALTH SCIENCES, INC.(Exact name of registrant as specified in its charter) Utah(State or other jurisdictionof incorporation or organization) 87-0500306(I.R.S. EmployerIdentification No.) 3838 West Parkway Blvd., Salt Lake City, Utah 84120(Address of principal executive offices, including zip code) (801) 954-7100(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: New York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNo As of May8, 2026, there were 18,463,011 outstanding shares of the registrant’s common stock, $0.001 par value. Auditor Location: Salt Lake City, UtahAuditor Firm ID: 185 USANA HEALTH SCIENCES, INC. FORM 10-Q For the Quarterly Period Ended April4, 2026 TABLE OF CONTENTS Cautionary Note Regarding Forward-Looking Statements and Certain Risks1PART I. FINANCIAL INFORMATIONItem 1Financial Statements (unaudited)4Condensed Consolidated Balance Sheets4Condensed Consolidated Statements of Comprehensive Income5Condensed Consolidated Statements of Stockholders’ Equity6Condensed Consolidated Statements of Cash Flows7Notes to Condensed Consolidated Financial Statements8-18Item 2Management’s Discussion and Analysis of Financial Condition and Results of Operations19-27Item 3Quantitative and Qualitative Disclosures About Market Risk27Item 4Controls and Procedures27PART II. OTHER INFORMATIONItem 1Legal Proceedings29Item 1ARisk Factors29Item 2Unregistered Sales of Equity Securities and Use of Proceeds29Item 5Other Information29Item 6Exhibits30Signatures31 Cautionary Note Regarding Forward-Looking Statements and Certain Risks This report contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. PrivateSecurities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the SecuritiesExchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact are “forward-lookingstatements” for purposes of federal and state securities laws, including any projections of earnings, revenue or other financial items;any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed newproducts; any statements regarding future economic conditions or performance; any statements of belief; and any statements ofassumptions underlying any of the foregoing. Forward-looking statements may include, but are not limited to, statements regardingfuture financial results, long-term value creation goals, focus and strategy, integration of acquisitions and performance expectationsregarding such acquisitions, productivity, raw material prices and related costs, supply chain, asset impairment, litigation,sustainability and governance efforts, compliance with current or proposed international laws and regulations, the impact of COVID-19 or other pandemics, or geo-political relationships, trade policies, tariffs, tensions, conflicts or wars on our operations. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “seek,” “believe,” “project,” “estimate,” "target",“expect,” “strategy,” "potential", “future